Last reviewed · How we verify
20vPnC (20vpnc)
At a glance
| Generic name | 20vpnc |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Vaccine |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Children (PHASE2)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (PHASE3)
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults (PHASE1, PHASE2)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants (PHASE2)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20vPnC CI brief — competitive landscape report
- 20vPnC updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI